Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: Systematic review of the literature and implications for future research

Gynecologic Oncology

Volumn 84, Issue 2, 2002, Pages 201-209

  Perez Gracia, Jose Luis ^a   Carrasco, Eva María ^a  

^a ELI LILLY AND COMPANY   (Spain)

Author keywords

Adjuvant therapy; Hormonal receptors; Hormonal therapy; Ovarian neoplasms; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER SURVIVAL; FUTUROLOGY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; OVARY CANCER; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; RESEARCH; REVIEW;

EID: 0036166523     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6489     Document Type: Review

References (78)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women
2. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma
3. Biological therapy of ovarian cancer: Current directions
4. Advanced ovarian carcinoma: Response to antiestrogen therapy
5. Remission of a chemotherapy resistant tumor of low malignant potential with tamoxifen
6. Subcutaneous metastasis from an ovarian carcinoma disappeared following tamoxifen therapy
7. Experience with tamoxifen use in ovarian cancer in the clinical practice setting
8. Oestrogen-responsive human breast cancer in long-term tissue culture
9. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture
10. Estrogen control of progesterone receptor in human breast cancer: Role of estradiol and antiestrogen
11. Estrogenic and antiestrogenic actions of tamoxifen in the female reproductive tract
12. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro
13. In vitro responsiveness of ovarian epithelial carcinomas to endocrine therapy
14. Estrogen and antiestrogen effects on the growth of human epithelial ovarian cancer in vitro
15. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines
16. Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line
17. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen
18. Responsiveness of patients with advanced ovarian cancer to tamoxifen: A Gynecologic Oncology Group study of second-line therapy in 105 patients
19. Tamoxifen in the treatment of recurrent ovarian carcinoma
20. Tamoxifen in platinum-refractory ovarian cancer: A gynecologic oncology group ancillary report
21. Phase II trial of tamoxifen in patients with advanced epithelial ovarian cancer
22. Hormonal therapy of ovarian cancer
23. Tamoxifen therapy in recurrent epithelial ovarian carcinoma
24. Tamoxifen in patients with advanced epithelial ovarian cancer
25. Hormonal palliation of chemoresistant ovarian cancer: Three consecutive phase II trials of the Mid-Atlantic oncology program
26. Tamoxifen in refractory ovarian cancer: The use of a loading dose schedule
27. Predictors of survival (OS) and time to progression (TTP) following second- or third-line treatment in advanced ovarian cancer (OVCA): An analysis of 744 patients (pts) treated with paclitaxel, docetaxel or high-dose epirubicin
28. A phase II study of tamoxifen in ovarian cancer
29. Tamoxifen therapy of epithelial ovarian cancer
30. Tamoxifen therapy for advanced ovarian cancer
31. Hormone receptors in ovarian carcinoma
32. Steroid-hormone receptors in breast cancer
33. The use of high-dose megestrol acetate in the treatment of ovarian adenocarcinoma
34. Hormone therapy in epithelial ovarian cancer
35. Tamoxifen for relapse of ovarian cancer
36. Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer
37. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer
38. Experience with hormonal therapy in advanced epithelial ovarian cancer
39. Treatment of metastatic disease
40. Antiestrogen as last-line treatment in epithelial ovarian cancer
41. Treatment of advanced ovarian carcinoma with tamoxifen: A phase II trial
42. Tamoxifen therapy in advanced ovarian cancer: A phase II study
43. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma
44. Advanced ovarian cancer: Correlation of histologic grade with response to therapy and survival
45. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience
46. Progestogen therapy for ovarian carcinoma
47. A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant tumors treated with medroxy-progesterone acetate
48. The role of hormonal therapy in the management of ovarian cancer
49. Endocrine role in ovarian cancer
50. Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial
51. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro
52. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumors
53. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum (II) by clomiphene and tamoxifen in human ovarian cancer cells
54. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies
55. Tamoxifen does not potentiate the effect of cisplatin in human ovarian cancer cells in vitro
56. Chemotherapy and hormonal therapy in combination
57. Tamoxifen-citrate counteracts the antitumor effects of citotoxic drugs in vitro
58. Luteinizing hormone-releasing hormone agonist triptorelin in combination with citotoxic chemotherapy in patients with advanced ovarian carcinoma
59. The use of luteinizing hormone-releasing hormone agonist and antagonist in gynecological cancers
60. Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71
61. The treatment of ovarian cancer with medroxyprogesterone acetate
62. Multi-agent chemotherapy with and without medroxyprogesterone acetate in the treatment of advanced ovarian cancer
63. Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: A pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin
64. Malignant tumors of the breast
65. Estrogen receptors in human ovarian epithelial carcinoma
66. Steroid receptors and ovarian tumors: Variation within primary tumors and between primary tumors and metastases
67. Changes in multiple or sequential estrogen receptor determinations in breast cancer
68. Estrogen receptor levels in multiple biopsies from patients with breast cancer
69. Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors
70. Tamoxifen for recurrent and progressive epithelial ovarian tumors
71. Endocrine therapy of breast cancer
72. Effects of tamoxifen in cardiovascular risk factors in postmenopausal women after 5 years of treatment
73. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women
74. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
75. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
76. The epidemiology of ovarian cancer
77. Second primary neoplasms following ovarian cancer
78. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study